JOURNAL OF VIROLOGY, Sept. 1993, p. 5146-5152
Vol. 67, No. 9
0022-538X/93/095146-07$02.00/0
Copyright ©) 1993, American Society for Microbiology
Protection against Retroviral Diseases after Vaccination Is
Conferred by Interference to Superinfection with
Attenuated Murine Leukemia Viruses
ANTOINE CORBIN AND MARC SITBON*
Laboratoire d'Oncologie Cellulaire et Moleculaire, Unite INSERM 363, Institut Cochin de Gene'tique
Moleculaire, Universite Paris V, 27 Rue Faubourg St-Jacques, 75014 Paris, France
Received 2 April 1993/Accepted 24 May 1993
A cell culture infected with a retrovirus becomes relatively
resistant to superinfection by a related retrovirus (40, 61).
This in vitro phenomenon, known as interference to superinfection, has been observed with all retroviral species
tested (40, 44, 55, 61). It involves the viral envelope glycoprotein (14, 20, 22, 23, 55), results from a restricted penetration into the cell (53, 54), and has been observed only when
both viruses share the same receptor (18, 21, 59, 60). A
mechanistic model has been postulated according to which
penetration of new virions is restricted as a result of direct
interaction of the viral envelope glycoprotein produced by
infected cells with its cellular receptor.
Chickens and mice express several endogenous envelopelike glycoproteins which confer resistance to diseases induced by exogenous viruses. It has been suggested that such
protection is due to a similar interference phenomenon in
vivo (25, 28, 38, 64). We reasoned that protection against
retroviral diseases by in vivo interference might also be
achieved through vaccinal exogenous infection. Most of the
retroviral models would not allow the testing of this hypothesis because involvement of an immune mechanism in protection could not be excluded. We chose the Friend murine
leukemia virus (F-MuLV) model because inoculation of mice
as newborns with this virus causes distinct pathogenic
effects and because these conditions of inoculation have
been shown to induce T-lymphocyte immune tolerance
against MuLV (10). Also, mice inoculated as newborns do
not develop MuLV-specific circulating antibodies (42, 48),
although this might also be due to deposition of immune
complexes in the kidneys (33). In mice inoculated as newborns, the virulent strain 57 of F-MuLV (34) induces succes*
sively a severe early hemolytic anemia (EHA) and an
anemiant erythroleukemia, generally readily detected at 2 to
3 and 6 to 8 weeks of age, respectively. Contrastingly and
despite good spreading ability, the closely related strain B3
of F-MuLV (30, 51) does not induce severe EHA, and
leukemia develops only after a marked latency which generally exceeds 6 months of age (46, 48, 51). Neonatal vaccination of mice with the attenuated F-MuLV B3 conferred
efficient protection against both diseases induced upon infection with F-MuLV 57 as well as against acute leukemia
induced by viral complexes containing spleen focus-forming
virus (SFFV) (17, 26). Furthermore, the use of MuLV strains
belonging to different interference groups allowed us to
establish that protection was observed only when vaccinal
and challenge viruses had envelopes which shared the same
receptor. We also described certain limitations in using
vaccination by interference with replication-competent retroviruses.
MATERIALS AND METHODS
Cell cultures, viruses, and viral stocks. All cell lines were
cultivated in Dulbecco's modification of Eagle's medium
(DMEM) complemented with glutamine (2 mM), penicillin
(50 IU ml-1), streptomycin (50 mg ml-1), and 10% heatinactivated fetal calf serum. The following viral strains were
used: the ecotropic F-MuLV 57 (30, 34), F-MuLV B3 (30,
51), and Moloney MuLV 8.2 (M-MuLV) (45), the amphotropic 4070A (Ampho) (21), the polytropic mink-cell focusinducing virus Fr-MCF-1 (MCF) (58), and the chimera
F/MCF Env, which contains the polytropic Fr-MCF-1 envelope in the F-MuLV 57 background (35). Viral stocks were
prepared on either NIH 3T3 or Mus dunni cells (29). Supernatants were removed from subconfluent infected cells 10 to
Corresponding author.
5146
Downloaded from http://jvi.asm.org/ on July 24, 2020 by guest
Cell cultures expressing a retroviral envelope are relatively resistant to superinfection by retroviruses which
bear envelopes using the same receptor. We tested whether this phenomenon, known as interference to
superinfection, might confer protection against retroviral diseases. Newborn mice first inoculated with the
attenuated strain B3 of Friend murine leukemia virus (F-MuLV) were protected against severe early hemolytic
anemia and nonacute anemiant erythroleukemia induced by the vinlent strain 57 of F-MuLV. Vaccinated
animals were also protected as adults against acute polycythemic erythroleukemia induced upon inoculation
with the viral complex containing the defective spleen focus-forming virus and F-MuLV 57 as helper virus.
Animals were inoculated as newborns, which is known to induce immune tolerance in mice, and the rapid
kinetics of protection, incompatible with the delay necessary for the immune response to develop, indicated that
protection was not due to an immune mechanism but rather was due to the rapid and long-lasting phenomenon
of interference. This result was confirmed by combining parental and envelope chimeric MuLV from different
interference groups as vaccinal and challenge viruses. Although efficient protection could be provided by
vaccination by interference, we observed that attenuated replication-competent retroviruses from heterologous
interference groups might exert deleterious synergistic effects.
VOL. 67, 1993
VACCINATION BY INTERFERENCE AGAINST MuLV DISEASES
0.05.
TIME OF INOCULATIONS
VACCINATION:
r-MuLV B63
CHALLENGE:
F-MuLV 57)
None
Day I
Day I
Day 2
Day 3
Day 4
None
Day 4
None
Day 4
Day 4
Day 4
Day 4
None
45-
,
:::
mm~~~~::
::U.N
:
40-
Uon.
t
(.7
o
3530-
a
mu.
one
n
......Um
m
m
~~~~~~a
mas
25-
FIG. 1. Rapid protection after vaccination with ecotropic MuLV
against severe EHA induced by F-MuLV 57. ICFW mice were
challenged with F-MuLV 57 at 4 days of age without vaccination or
after vaccination with F-MuLV B3 at 1, 2, 3, or 4 days of age, as
indicated. Hematocrits from unchallenged animals vaccinated at 1
day of age and noninoculated animals are also shown. Both viral
stocks were adjusted to 105 focus-forming units per ml. Hematocrits
were determined from bleeding series between 16 and 24 days of
age. Only hematocrits of the lowest series are shown for each group.
Severe EHA is characterized by hematocrits below 35%. Closed
squares correspond to individual mice; open squares indicate the
mean hematocrits + standard error of the mean for each group.
RESULTS
Rapid protection against EHA and nonacute erythroleukemia after preinoculation with F-MuLV B3. Mice inoculated at
4 days of age with the virulent strain 57 of F-MuLV
developed a severe EHA at 2 to 3 weeks of age with
hematocrits below 35% (Fig. 1) and an anemiant erythroleukemia with gross splenomegaly 3 to 5 weeks later (Fig. 2),
whereas F-MuLV B3 induced only mild EHA (Fig. 1).
Animals preinoculated as newborns with F-MuLV B3 and
challenged 3 days later with F-MuLV 57 did not develop
severe EHA (Fig. 1). We evaluated the delay between
preinoculation and challenge necessary for the establishment
of this protection. As shown in Fig. 1, significant protection
against severe EHA, although partial, was observed even
when preinoculation and challenge were only 1 day apart
-/J4 (15)
0
o0
0)
o)
0)
0T
Age (months)
FIG. 2. Protection after vaccination with F-MuLV B3 against
anemiant erythroleukemia induced by F-MuLV 57. Occurrence of
leukemia was monitored by palpation in nonvaccinated mice (-/J4)
and in mice vaccinated with F-MuLV B3 at 1 (J1/J4) or 2 (J2/J4) days
of age before challenge at day 4 with F-MuLV 57. The number of
animals in each group is indicated in parentheses.
Downloaded from http://jvi.asm.org/ on July 24, 2020 by guest
18 h after the replacement of the medium, filtered (0.45-,umpore-size filter), and stored in aliquots at -60°C. SFFV viral
stocks were prepared as follows. For SFFV/F-MuLV stock,
M. dunni cells were infected at a high multiplicity of infection (MOI) with helper-free SFFV stock prepared from the
T-2 trans-complementing clone 3B2 (63) and superinfected
with F-MuLV 57 at a low MOI; stocks were obtained from
these cells when F-MuLV infection was confluent as tested
by focal immunofluorescence assay (FIA) (50). For SFFV/
Ampho stock, M. dunni cells were infected at a high MOI
with a viral preparation obtained from helper-free NRK/
SFFVp cells (2) infected with Ampho. Viral stocks were
titrated by FIA as previously described (50) with monoclonal
antibodies discriminating among the envelope glycoproteins
of F-MuLV, M-MuLV, Ampho, and polytropic viruses (8, 9,
16).
Origin, infection, and clinical evaluation of mice. All experimentation was conducted on ICFW mice, an inbred line
derived from Carworth Farms White outbred mice (62).
Newborn mice were inoculated intraperitoneally with 0.05
ml of viral stock between 1 to 4 days of age as indicated.
Young adult mice (6 to 7 weeks of age) were inoculated
intravenously at the retro-orbital sinus with 0.2 ml of viral
stock. As described previously (51), hematocrits (the volume
of erythrocytes expressed as the percentage of blood volume) were determined on blood samples taken under ether
anesthesia by puncture at the retro-orbital sinus with 20-,u
heparinized capillary tubes (Drummond Scientific Company,
Broomall, Pa.), and EHA was determined from three bleedings performed at 3-day intervals from 16 to 24 days of age.
For evaluation of protection, in each litter, only the lowest
hematocrits of the bleeding series were taken into account.
The anemiant erythroleukemia induced by F-MuLV 57 was
monitored by regular spleen palpation under ether anesthesia at approximately 2-week intervals. Mice displaying gross
organ enlargement were bled for the determination of hematocrits, and diagnoses were confirmed by sacrifice and
autopsy of moribund animals. The diagnosis of anemiant
erythroleukemia depended on the association of severe
anemia (hematocrits less than 35%) with hepatosplenomegaly and the absence of any enlargement of lymph nodes
or thymus. Mice challenged with SFFV stocks were monitored weekly by palpation of the spleen and determination
of hematocrits. Acute polycythemic erythroleukemia was
characterized by the rapid onset of gross splenomegaly
followed by an imposing polycythemy with hematocrits up
to 85%.
Infectious center assays. Animals were sacrificed at 21 to 25
days of age, and spleens were collected and dispersed in
complete DMEM. Spleen cell suspensions were washed
once and adjusted to 107 live nucleated cells ml-1. Serial
dilutions of splenocytes were prepared in complemented
medium, and 105, 104, 103, or 102 cells in 1 ml were added to
approximately 105 NIH 3T3 cells seeded the day before on
60-mm-diameter culture dishes. After approximately 18 h of
cocultivation, splenocytes were removed and cultures were
permitted to grow to confluency before infectious centers
were enumerated by FIA (49, 50) using monoclonal antibodies discriminating between F- and M-MuLV (9, 16) (generous gifts of B. Chesebro).
Statistical analyses. The means of hematocrits were compared by using the two-tailed t test. Differences were considered statistically significant when P values were less than
5147
J. VIROL.
CORBIN AND SITBON
5148
VIRAL INOCULATIONS
VACCINATION
(Day 1
CHALLENGE
(Day 4)
None
45
0
<)
0
M-MuLV
Amphe
MCF
F-MuLV 57 F-MuLV 57 F-MuLV 57 F-MuLV 57 F-MuLV 57
I
r-
*-
F-MuLV B3
F-MuLV B3
M|F
I F-MuLV B3
F/NCfcEnv FlAC Env I
None
M-MuLV
Aaph
AMCF
None
None
None
-
45
40
40
35
35
--
!-
LU
30
30
i-
.-
LI-11;K
I
25
25
FIG. 3. Protection against severe EHA with vaccinal and challenge MuLV belonging to the same interference group. ICFW mice were
vaccinated at 1 day of age with attenuated MuLV from the ecotropic (F-MuLV B3 and M-MuLV), amphotropic (Ampho), or polytropic
(MCF) interference groups and were challenged at 4 days of age with either the ecotropic F-MuLV 57 or the polytropic chimeric virus F/MCF
Env (35). Vaccinal viral stocks (F-MuLV B3, M-MuLV, Ampho, and MCF) had titers of 105 to 7.106 focus-forming units per ml; challenge
viral stocks (F-MuLV 57 and F/MCF Env) had titers of approximately 105 focus-forming units per ml.
(mean hematocrits of 35% versus 30%; P < 10-3), and
optimal protection with mean hematocrits of approximately
38%, similar to levels observed in unchallenged animals, was
observed as rapidly as 2 days after preinoculation. Such
rapid establishment of protection after preinoculation of the
attenuated F-MuLV B3 was also observed with regard to
appearance of erythroleukemia. Thus, preinoculation performed 2 days before challenge considerably increased the
latency (Fig. 2), and preinoculation performed 3 days before
challenge completely prevented the appearance of erythroleukemia for up to 5 months, similar to what was observed in
unchallenged animals. Animals challenged only a few minutes after preinoculation were also partially protected, since
they developed erythroleukemia after a significantly increased latency compared with nonvaccinated animals (3.5
months versus 1.5 months) (not shown).
Protection requires that vaccinal and challenge viruses
belong to the same interference group. The remarkably rapid
establishment of protection indicated that a nonimmune
mechanism was involved. We tested whether this nonimmune protection was indeed due to an interference-like
mechanism. For this purpose, we used vaccinal and challenge viruses belonging to different interference groups such
as MuLV of the ecotropic, amphotropic, and polytropic
groups as well as a chimeric virus which substituted the
envelope gene of the polytropic MCF for that of the ecotropic F-MuLV 57 (F/MCF Env) (35). As opposed to the results
of vaccination with the ecotropic F-MuLV B3, heterologous
vaccination was not protective. Thus, newborns vaccinated
with either Ampho or MCF were generally not protected
against severe EHA after challenge with the ecotropic
F-MuLV 57 (Fig. 3). Moreover, animals vaccinated with the
ecotropic F-MuLV B3 developed severe EHA upon challenge with the polytropic F/MCF Env, whereas most mice
vaccinated with MCF and challenged with F/MCF Env did
not develop severe EHA (Fig. 3). Also, animals vaccinated
with either of the nonecotropic viruses developed erythroleukemia as rapidly as did nonvaccinated animals upon
challenge with F-MuLV 57 (not shown). These results con-
firmed that protective vaccination developed mostly through
in
vivo
interference.
Efficiency of vaccination by interference may vary between
viruses from the same interference group. To further examine
characteristics of vaccination by interference, we used as
vaccinal virus the ecotropic M-MuLV, which belongs to the
same interference group as F-MuLV but has a different
target cell spectrum. Thus, animals inoculated as newborns
with M-MuLV have only a very slight drop of hematocrits
(41.5% versus 43% in noninoculated animals) (Fig. 3) and
develop only thymomas after a longer latency than erythroleukemia induced by F-MuLV (45, 47). We observed that
mice vaccinated with M-MuLV and challenged with
F-MuLV 57 were efficiently protected from severe EHA
(Fig. 3). Nonetheless, despite this efficient protection against
severe EHA, approximately one-third of the animals vaccinated with M-MuLV developed erythroleukemia within 2
months (not shown).
Protective vaccination by interference may require restriction without suppression of spreading of the challenge virus.
Because the protection was only partial after use of a
heterologous virus from the same interference group, as
described above for M-MuLV, we tested whether such
vaccination interfered efficiently with the in vivo overall
spreading of the challenge virus. Distinction between vaccinal and challenge ecotropic viruses was possible when
M-MuLV and F-MuLV strains were combined by using
monoclonal antibodies (9, 16) which allowed the specific
quantitation of cells productively infected with either virus
(Fig. 4). Although we observed that vaccination with either
M-MuLV (Fig. 4A) or F-MuLV (Fig. 4B) interfered significantly with the dissemination of the other, several animals
had reduced but still significant levels of cells infected with
the challenge virus. Therefore, the actual level of in vivo
interference with the spreading of F-MuLV observed after
vaccination with M-MuLV was sufficient to fully protect
against severe EHA but did not allow efficient protection
against erythroleukemia.
Vaccination by interference protects against SFYV-induced
Downloaded from http://jvi.asm.org/ on July 24, 2020 by guest
25
=:>
VACCINATION BY INTERFERENCE AGAINST MuLV DISEASES
VOL. 67, 1993
A F-MuLV infectious
VACCINATION:
None
centers
M-MuLV
CHALLENGE: F-MuLV 57 F-MuLV 57
I
10i
B
M-MuLV infectious centers
VACCINATION:
None
F-MuLV B3
CHALLENGE:
M-MuLV
M-MuLV
I
106
I
on
on
Ems
o1
o0-
0l-
a
a
a
o
a
no
an
10
CU
<10
.
FIG. 4. In vivo interference between spreading of the ecotropic
M- and F-MuLV. (A) Nonvaccinated mice or mice vaccinated
neonatally with M-MuLV were challenged at 4 days of age with
F-MuLV 57. (B) Nonvaccinated mice or mice vaccinated with
F-MuLV B3 were challenged at 4 days of age with M-MuLV. The
same viral stocks as described in the legend to Fig. 3 were used.
Animals were sacrificed at 21 to 25 days of age, and the spreading of
the challenge virus was determined by FIA (50) using envelopespecific monoclonal antibodies (generous gift of B. Chesebro).
may stimulate the pathogenic properties of
challenge viruses from heterologous interference groups. Efficient protection against nonacute diseases induced by
MuLV lacking an oncogene could be achieved after vaccination by interference. We also tested the efficiency of
vaccination by interference in the protection against a more
potent leukemogenic process, such as that triggered through
the oncogene-like SFFV defective envelope (26). The SFFV/
F-MuLV viral complex induced an acute polycythemic
erythroleukemia within 2 to 3 weeks after inoculation of
adult mice. Animals vaccinated as newborns with F-MuLV
B3 were efficiently protected against disease induced by
SFFV/F-MuLV and were still free of disease over 15 weeks
after challenge (Table 1). We also tested combinations of
acute disease but
TABLE 1. Effects of vaccinations with MuLV from different
interference groups on induction of polycythemic
erythroleukemia by SFFV
Vaccinationa
None
F-MuLV
Ampho
MCF
None
Ampho
F-MuLV
MCF
No.
Time of first
appearance of disease
(wk after challenge)
Challengeb
diseased/total
SFFV/F-MuLV
SFFV/F-MuLV
SFFV/F-MuLV
SFFV/F-MuLV
SFFV/Ampho
SFFV/Ampho
SFFV/Ampho
SFFV/Ampho
5/5
3
>15
3
3
0/5
8/8
> 12
inoculated
0/5
3/3
4/4
1/5
4/4
5
3
3
a Newborn ICFW mice were vaccinated with the ecotropic F-MuLV B3,
the amphotropic MuLV 4070A (Ampho), or the polytropic MCF, with titers of
105 to 106 focus-forming units per ml. Vaccinal strains homologous to the
SFFV helper virus are in bold type.
b Performed at 45 days of age with SFFV viral complexes containing either
ecotropic F-MuLV 57 (SFFV/F-MuLV) or Ampho (SFFV/Ampho) as helper
virus.
vaccinal and challenge helper viruses from different interference groups. The observation that vaccination with Ampho
or polytropic MCF did not prevent polycythemic erythroleukemia induced after challenge with the ecotropic SFFV/
F-MuLV complex (Table 1) confirmed that protection in this
model was also based on an interference mechanism. We
further examined this aspect by using the SFFV/Ampho viral
complex. The already weak virulence of this SFFV/Ampho
complex was no longer observed upon vaccination with
Ampho, although the small sample size did not allow evaluation of the statistical significance of this result (Table 1).
More interestingly, we observed that all animals vaccinated
either with the ecotropic F-MuLV B3 or with the polytropic
MCF were rapidly and severely diseased after challenge with
SFFV/Ampho. These results indicated that a deleterious
synergy occurred in this model when vaccinal and challenge
viruses from heterologous interference groups were used.
To test whether these protective and deleterious effects of
vaccination by interference to superinfection could be observed even in nontolerized animals, mice were vaccinated
with either the attenuated F-MuLV B3 or Ampho at 1 month
of age and challenged 2 months later with either SFFV/FMuLV or SFFV/Ampho. Protective or deleterious effects
were similar to those observed in animals vaccinated as
newborns (data not shown).
DISCUSSION
Natural protection in mice against several MuLV diseases
has been correlated with endogenous expression of glycoproteins homologous to retroviral envelopes (4, 5, 18, 25, 41,
43). In the case of the Fv-4 locus (56), the resistant allele has
been cloned and shown to encode an envelope-like glycoprotein (24, 28). During in vitro experiments, it has been
shown that expression of Fv-4' in cell lines decreased their
susceptibility to infection by ecotropic MuLV (27), suggesting that in vivo protection linked to this gene is due to
interference to superinfection. However, since this envelope-like glycoprotein is defective and efficiently incorporated into virions, it has also been suggested that decreased
susceptibility might be due to a trans-dominant negative
effect on production of infectious virions (31). Protection
against MuLV-induced pathogenesis has also been reported
after exogenous preinoculation, and nonimmune mechanisms have been evoked in certain cases (7, 15, 39). In the
present study, nonimmune vaccination against the lytic and
nonacute leukemogenic effects of the virulent prototype of
F-MuLV was achieved in newborn mice preinoculated with
a replication-competent but weakly pathogenic strain of
F-MuLV. This neonatal vaccination was also efficiently
protective against acute erythroleukemia induced in adult
mice by a viral complex composed of the SFFV and a helper
virus. Moreover, significant protection against F-MuLVinduced erythroleukemia occurred even when vaccination
and challenge were performed within a few minutes of each
other, and maximal protection against both the early lytic
and late leukemogenic effects was achieved when vaccination and challenge were performed within an interval of only
3 days. That protection following vaccination could be
established so rapidly in mice immunologically tolerized by
newborn vaccination (10, 42, 48) confirmed that protection in
this model was based upon nonimmune mechanisms. Further evidence for an in vivo interference mechanism was
obtained by using combinations of vaccinal and challenge
viruses from different interference groups including an env
chimera MuLV. Protective interference is expected to de-
Downloaded from http://jvi.asm.org/ on July 24, 2020 by guest
m.
<10
5149
5150
CORBIN AND SITBON
tween their envelopes and the ecotropic receptor (1).
Nevertheless, interference sufficient to prevent pathogenesis
might not require that expression of the interfering envelope
occurred in all potential target cells. Thus, we observed that
reduction without abolition of F-MuLV spreading by
M-MuLV vaccination was sufficient to protect the animals
from severe EHA, and protection against erythroleukemia,
although partial, was still significant. Because of lack of
reagents allowing distinctive quantitation of the highly related attenuated and virulent strains of F-MuLV (48), precise
measurements of spreading of the challenge virus F-MuLV
57 upon vaccination with F-MuLV B3, which conferred
maximum protection against erythroleukemia, could not be
obtained. Nevertheless, our preliminary data indicated that
this more efficient vaccination did not completely abolish
spreading of the challenge virus (not shown). This finding
suggested that significant protection against retroviral diseases might be conferred by vaccination which would restrict without abolishing accessibility of target cells to infection by the challenge virus.
It has been recently reported that infection by mouse
mammary tumor virus was blocked in mice in which target
cells essential for dissemination had been deleted by transgenesis of a superantigen (19). Vaccines which would include nonclassical protective mechanisms leading to restricted accessibility of the potential target cells might thus
be considered for several retrovirally induced pathogeneses.
Among the vaccine strategies developed so far, the use of
live attenuated viruses seems to allow such alternative
mechanisms to occur in addition to immune responses. In
this regard, it is interesting to note that efficient protection
against disease induced by simian immunodeficiency virus
has been recently achieved by using a live attenuated virus
(13). It would be of interest to evaluate whether some
nonimmune mechanism(s) played any role in the latter
model. It is important to note that vaccination by interference is based on recognition of the cellular receptor, a
conserved feature among viruses from the same group, and
thus might offer an additional mechanism of protection
against hypervariable viral strains. Nevertheless, our results
on possible pathogenic synergy between attenuated vaccinal
and challenge strains from heterologous groups emphasize
that possible facilitation of heterologous viral diseases by
replication-competent vaccinal retroviruses should still be of
some concern.
ACKNOWLEDGMENTS
We are indebted to B. Chesebro for generous gifts of monoclonal
antibodies and to S. Ruscetti, L. Wolff, and A. Oliff for kindly
providing the F/MCF env chimera and SFFV-producing cell lines;
we thank F. Pozo, P. Varlet, and the animal care staff for excellent
assistance, G. Pancino, J. Richardson, P. Sonigo, and the scientific
staff of ICGM for helpful discussions and comments on the manuscript, and S. Gisselbrecht for continuous support.
A.C. is supported by a fellowship from the Fondation pour la
Recherche Medicale (Paris).
REFERENCES
1. Albritton, M. L., L. Tseng, D. Scadden, and J. M. Cunningham.
1989. A putative murine ecotropic retrovirus receptor gene
encodes a multiple membrane-spanning protein and confers
susceptibility to virus infection. Cell 57:659-666.
2. Barbacid, M., D. H. Troxler, E. M. Scolnick, and S. A. Aaronson. 1978. Analysis of translational products of the Friend strain
of spleen focus-forming virus. J. Virol. 27:826-830.
3. Bosze, Z., H.-J. Thiesen, and P. Charnay. 1986. A transcriptional enhancer with specificity for erythroid cells is located in
Downloaded from http://jvi.asm.org/ on July 24, 2020 by guest
pend upon sufficient spreading of the vaccinal virus in key
target cells, which would prevent dissemination of the challenge virus. Accordingly, we observed that vaccination
significantly hampered in vivo spreading of the challenge
virus and was inefficient when we used an F-MuLV mutant
which was altered in its early spreading abilities due to a
defect in the production of glycosylated forms of Gag (11).
Because severe EHA and nonacute anemiant erythroleukemia induced by F-MuLV develop only in mice inoculated
as newborns and are transient and slow processes, respectively, we further evaluated protection after vaccination by
interference against the more virulent acute polycythemic
erythroleukemia induced by SFFV. This disease, which is
dependent on an oncogene-like activation, develops very
rapidly even in mice inoculated as adults (26). Vaccination
by interference in newborns also protected against the acute
SFFV disease induced after challenge of the animals as
adults, with protection extending beyond 5 months. Pathogenesis of the defective SFFV depends on the presence of a
replication-competent helper virus, and an SFFV viral complex which comprises the amphotropic virus as a helper,
SFFV/Ampho, was weakly pathogenic, most likely because
of lower in vivo spreading of Ampho (32). Surprisingly, we
found that newborn vaccination with MuLV from heterologous interference groups significantly accelerated the disease induced by the weakly virulent SFFV/Ampho complex.
Our results are in agreement with the data reported by
Mitchell and Risser on spreading of these SFFV complexes
in animals preinoculated as adults with homologous or
heterologous viruses (32). The precise mechanism of the
synergistic deleterious effect that we observed in the SFFV
disease remains unclear. In the models described in both
studies, inoculation with F-MuLV leads to production of
recombinant polytropic viruses, and an amphotropic-induced polytropic class distinct from the ecotropic-induced
polytropic class has also been described (36, 37). It is
therefore possible that recurrent superinfections with viruses from distinct interference groups, ecotropic, amphotropic, and polytropic, might lead to formation of new,
fast-spreading SFFV complexes. It is also conceivable that
although vaccination with the live attenuated virus is minimally pathogenic, it might increase the erythroid cell pool
available for infection and transformation by the SFFVcontaining viral complex. Finally, immune response defects
consequent to tolerization might explain this synergistic
effect, similarly to what has been observed in an avian model
(12). However, the latter mechanism remains very unlikely,
since a synergistic effect was observed even when nontolerized adult mice were vaccinated and challenged.
Although interference is theoretically expected to occur
between viruses from the same group, we observed only
partial protection against ecotropic F-MuLV diseases when
vaccination was performed with the fully replicative ecotropic M-MuLV. Levels of F- and M-MuLV gene expression
appear to be significantly different in the erythroid and
lymphoid cellular compartments (3, 57). Such differences
most likely explain the different cellular specificity of their
leukemogenic effects (6, 52). Similarly, less efficient protection against F-MuLV-induced erythroleukemia after
M-MuLV vaccination than that observed after F-MuLV B3
vaccination might be due to lower expression of the potentially interfering M-MuLV envelope in the target cells,
whose infection is critical for pathogenesis induced by the
challenge virus. However, it cannot be excluded that differences between F- and M-MuLV in protection against erythroleukemia reflected intrinsic differences of interaction be-
J. VIROL.
VOL. 67, 1993
VACCINATION BY INTERFERENCE AGAINST MuLV DISEASES
23. Hunsmann, G., V. Moenning, L. Pister, E. Seifert, and W.
Schafer. 1974. Properties of mouse leukemia virus. VIII. The
major viral glycoprotein of Friend leukemia virus. Seroimmunological interfering and hemagglutinating capacities. Virology
62:307-318.
24. Ikeda, H., F. Laigret, M. A. Martin, and R. Repaske. 1985.
Characterization of a molecularly cloned retroviral sequence
associated with Fv-4 resistance. J. Virol. 55:768-777.
25. Ikeda, H., and T. Odaka. 1983. Cellular expression of murine
leukemia virus gp7O related antigen on thymocytes of uninfected
mice correlates with Fv-4 gene controlled resistance to Friend
leukemia virus infection. Virology 128:127-139.
26. Kabat, D. 1989. Molecular biology of Friend viral erythroleukemia. Curr. Top. Microbiol. Immunol. 148:1-42.
27. Kai, K., H. Sato, and T. Odaka. 1986. Relationship between the
resistance to Friend murine leukemia virus infection and the
expression of murine leukemia virus-gp7O-related glycoprotein
on cell surface of Balb/c-Fv-4W mice. Virology 150:509-512.
28. Kozak, C. A., N. J. Gromet, H. Ikeda, and C. E. Buckler. 1984.
A unique sequence related to the ecotropic murine leukemia
virus is associated with the Fv-4 resistance gene. Proc. Natl.
Acad. Sci. USA 81:834-837.
29. Lander, M. R., and S. K. Chattopadhyay. 1984. A Mus dunni
cell line that lacks sequences closely related to endogenous
murine leukemia viruses and can be infected by ecotropic,
amphotropic, xenotropic, and mink cell focus-forming viruses.
J. Virol. 52:695-698.
30. Linemeyer, D. L., S. K. Ruscetti, J. G. Menke, and E. M.
ScolnicL 1980. Recovery of biologically active spleen focusforming virus from molecularly cloned spleen focus-forming
virus-pBR322 circular DNA by cotransfection with infectious
type C retroviral DNA. J. Virol. 35:710-721.
31. Masuda, M., and H. Yoshiklra. 1990. Construction and characterization of recombinant Moloney murine leukemia virus bearing the mouse Fv-4 env gene. J. Virol. 64:1033-1043.
32. Mitchell, T., and R. Risser. 1992. Interference established in
mice by infection with Friend murine leukemia virus. J. Virol.
66:5696-5702.
33. Oldstone, M. B. A. 1975. Virus neutralization and virus-induced
immune complex disease. Virus-antibody union resulting in
immunoprotection or immunologic injury-two sides of the
same coin. Prog. Med. Virol. 19:84-119.
34. Oliff, A. I., G. L. Hager, E. H. Chang, E. M. Scolnick, H. W.
Chan, and D. R. Lowy. 1980. Transfection of molecularly cloned
Friend murine leukemia virus DNA yields a highly leukemogenic helper-independent type C virus. J. Virol. 33:475-486.
35. Oliff, A., M. D. McKinney, and 0. Agranovsky. 1985. Contribution of the gag and pol sequences to the leukemogenicity of
Friend murine leukemia virus. J. Virol. 54:864-868.
36. Ott, D., R. Friedrich, and A. Rein. 1990. Sequence analysis of
amphotropic and 1OAl murine leukemia viruses: close relationship to mink cell focus-inducing viruses. J. Virol. 64:757-766.
37. Rasheed, S., B. K. Pal, and M. B. Gardner. 1982. Characterization of a highly oncogenic murine leukemia virus from wild
mice. Int. J. Cancer 29:345-350.
38. Robinson, H. L., S. M. Astrin, A. M. Senior, and F. H. Salazar.
1981. Host susceptibility to endogenous viruses: defective,
glycoprotein-expressing proviruses interfere with infections. J.
Virol. 40:745-751.
39. Rowe, W. P. 1963. Resistance of mice infected with Moloney
leukemia virus to Friend virus infection. Science 141:40-41.
40. Rubin, H. 1960. A virus in chick embryos which induces
resistance in vitro to infection with Rous sarcoma virus. Proc.
Natl. Acad. Sci. USA 46:1105-1119.
41. Ruscetti, S., L. Davis, J. Field, and A. Oliff. 1981. Friend murine
leukemia virus-induced leukemia is associated with the formation of mink cell focus-inducing viruses and is blocked in mice
expressing endogenous mink cell focus-inducing xenotropic
viral envelope genes. J. Exp. Med. 154:907-920.
42. Ruscetti, S., J. Field, L. Davis, and A. Oliff. 1982. Factors
determining the susceptibility of NIH swiss mice to erythroleukemia induced by Friend murine leukemia virus. Virology
117:357-365.
Downloaded from http://jvi.asm.org/ on July 24, 2020 by guest
the long terminal repeat of the Friend murine leukemia virus.
EMBO J. 5:1615-1623.
4. Bulier, R. S., M. Sitbon, and J. L. Portis. 1988. The endogenous
mink cell focus-forming (MCF) gp7O linked to the Rmcf gene
restricts MCF virus replication in vivo and provides partial
resistance to erythroleukemia induced by Friend murine leukemia virus. J. Exp. Med. 167:1535-1546.
5. Buller, R. S., K. Wehrly, J. L. Portis, and B. Chesebro. 1990.
Host genes conferring resistance to a central nervous system
disease induced by a polytropic recombinant Friend murine
retrovirus. J. Virol. 64:493-498.
6. Chatis, P. A., C. A. Holland, J. W. Hartley, P. W. Rowe, and N.
Hopkins. 1983. Role for the 3' end of the genome in determining
disease specificity of Friend and Moloney murine leukemia
viruses. Proc. Natl. Acad. Sci. USA 80:4408 4411.
7. Chattopadhyay, S. K., H. C. Morse Ill, M. Makino, S. K.
Ruscetti, and J. W. Hartley. 1989. Defective virus is associated
with induction of murine retrovirus-induced immunodeficiency
syndrome. Proc. Natl. Acad. Sci. USA 86:3862-3866.
8. Chesebro, B., J. L. Portis, K. Wehrly, and J. Nishio. 1983. Effect
of murine host genotype on MCF virus expression, latency and
leukemia cell type of leukemias induced by Friend murine
leukemia helper virus. Virology 128:221-233.
9. Chesebro, B., K. Wehrly, M. Cloyd, W. Britt, J. Portis, J.
Collins, and J. Nishio. 1981. Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virusinduced erythroleukemia cells: Friend-specific and FMR-specific antigens. Virology 112:131-144.
10. Collavo, D., P. Zanovello, G. Biasi, and L. Chieco-Bianchi. 1981.
T lymphocyte tolerance and early appearance of virus-induced
cell surface antigens in Moloney-murine leukemia virus neonatally injected mice. J. Immunol. 126:187-193.
11. Corbin, A., J. P. Richardson, and M. Sitbon. Unpublished
results.
12. Crittenden, L. B., S. McMahon, M. S. Halpern, and A. M.
Fadly. 1987. Embryonic infection with the endogenous avian
leukosis virus Rous-associated virus-0 alters responses to exogenous avian leukosis virus infection. J. Virol. 61:722-725.
13. Daniel, M. D., F. Kirchhoff, S. C. Czajak, P. K. Sehgal, and
R. C. Desrosiers. 1992. Protective effects of a live attenuated
SIV vaccine with deletion in the nef gene. Science 258:19381941.
14. DeLarco, J., and G. J. Todaro. 1976. Membrane receptors for
murine leukemia viruses: characterization using the purified
viral envelope glycoprotein, gp7l. Cell 8:365-371.
15. De Rossi, A., E. D'Andrea, G. Biasi, D. Callavo, and L.
Chieco-Bianchi. 1983. Protection from spontaneous lymphoma
development in SJL/J(v+) mice neonatally injected with dualtropic SJL-151 virus. Proc. Natl. Acad. Sci. USA 80:2775-2779.
16. Evans, L. H., R. P. Morrison, F. G. Malik, J. Portis, and W. J.
Britt. 1990. A neutralizable epitope common to the envelope
glycoproteins of ecotropic, polytropic, xenotropic, and amphotropic murine leukemia viruses. J. Virol. 64:6176-6183.
17. Friend, C. 1957. Cell-free transmission in adult Swiss mice of a
disease having the character of a leukemia. J. Exp. Med.
105:302-318.
18. Gardner, M. B., S. Rasheed, B. K. Pal, J. D. Estes, and S. J.
O'Brien. 1980. Akvr-1, a dominant murine leukemia virus restriction gene, is polymorphic in leukemia-prone wild mice.
Proc. Natl. Acad. Sci. USA 77:531-535.
19. Golovkina, T. V., A. Chervonsky, J. P. Dudley, and S. R. Ross.
1992. Transgenic mouse mammary tumor virus superantigen
expression prevents viral infection. Cell 69:637-645.
20. Hanafusa, H. 1965. Analysis of the defectiveness of Rous
sarcoma virus. III. Determining influence of a new helper virus
on the host range and susceptibility to interference of RSV.
Virology 25:248-255.
21. Hartley, J. W., and W. P. Rowe. 1976. Naturally occurring
murine leukemia viruses in wild mice: characterization of a new
"amphotropic" class. J. Virol. 19:19-25.
22. Heard, J. M., and 0. Danos. 1991. An amino-terminal fragment
of the Friend murine leukemia virus envelope glycoprotein
binds the ecotropic receptor. J. Virol. 65:4026-4032.
5151
5152
J. VIROL.
CORBIN AND SITBON
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
Hartley, and N. Hopkins. 1990. Mutation of the core of adjacent
LVb elements of the Moloney murine leukemia virus enhancer
alters disease specificity. Genes Dev. 4:233-242.
Steck, F. T., and H. Rubin. 1966. The mechanism of interference
between an avian leukosis virus and Rous sarcoma virus. I.
Establishment of interference. Virology 29:628-641.
Steck, F. T., and H. Rubin. 1966. The mechanism of interference
between an avian leukosis virus and Rous sarcoma virus. II.
Early steps of infection by RSV under conditions of interference. Virology 29:642-653.
Stevenson, M., C. Meier, A. M. Mann, N. Chappman, and A.
Wasiak. 1988. Envelope glycoprotein of HIV induces interference and cytolysis resistance in CD4+ cells: mechanism for
persistence in AIDS. Cell 53:483-496.
Suzuld, S. 1975. Fv-4: a new gene affecting the splenomegaly
induction by Friend leukemia virus. Jpn. J. Exp. Med. 45:437478.
Thiesen, H.-J., Z. Bosze, L. Henry, and P. Charnay. 1988. A
DNA element responsible for the different tissue specificities of
Friend and Moloney retroviral enhancers. J. Virol. 62:614-618.
Troxler, D. H., E. Yuan, D. Linemeyer, S. Ruscetti, and E. M.
Scolnick. 1978. Helper independent mink cell focus-inducing
strains of Friend murine type-C virus: potential relationship to
the origin of replication-defective spleen focus-inducing virus. J.
Exp. Med. 148:639-653.
Vogt, P. K., and R. Ishizaki. 1965. Reciprocal patterns of genetic
resistance to avian tumor viruses in two lines of chickens.
Virology 26:664-672.
Vogt, P. K., and R. Ishizaki. 1966. Patterns of viral interference
in the avian leukosis and sarcoma complex. Virology 30:368374.
Weiss, R., N. Teich, H. Varmus, and J. Coffin. 1984. RNA tumor
viruses, p. 210-260. Cold Spring Harbor Laboratory, Cold
Spring Harbor, N.Y.
Wendling, F., F. Moreau-Gachelin, and P. Tambounrin. 1981.
Emergence of tumorigenic cells during the course of Friend
virus leukemias. Proc. Natl. Acad. Sci. USA 78:3614-3618.
Wolff, L., and S. Ruscetti. 1985. Malignant transformation of
erythroid cells in vivo by introduction of a nonreplicating
retrovirus vector. Science 228:1549-1552.
Yoshikura, H., Y. Naito, and K. Moriwaki. 1979. Unstable
resistance of G mouse fibroblasts to ecotropic murine leukemia
virus infection. J. Virol. 29:1078-1086.
Downloaded from http://jvi.asm.org/ on July 24, 2020 by guest
43. Ruscetti, S., R. Matthai, and M. Potter. 1985. Susceptibility of
BALB/c mice carrying various DBA/2 genes to development of
Friend murine leukemia virus-induced erythroleukemia. J. Exp.
Med. 162:1579-1587.
44. Sarma, S. P., M. P. Cheong, J. W. Hartley, and R. J. Huebner.
1967. A viral interference test for murine leukemia viruses.
Virology 33:180-183.
45. Shoemaker, C., S. Goff, E. Gilboa, M. Paskind, S. W. Mitra, and
D. Baltimore. 1980. Structure of a cloned circular Moloney
murine leukemia virus DNA molecule containing an inverted
segment: implications for retrovirus integration. Proc. Natl.
Acad. Sci. USA 77:3932-3936.
46. Sitbon, M., L. d'Auriol, H. Ellerbrok, C. Andre, J. Nishio, S.
Perryman, F. Pozo, S. F. Hayes, K. Wehrly, P. Tambourin, F.
Galibert, and B. Chesebro. 1991. Substitution of leucine for
isoleucine in a sequence highly conserved among retroviral
envelope surface glycoproteins attenuates the lytic effect of the
Friend murine leukemia virus. Proc. Natl. Acad. Sci. USA
88:5932-5936.
47. Sitbon, M., H. Ellerbrok, F. Pozo, J. Nishio, S. F. Hayes, L. H.
Evans, and B. Chesebro. 1990. Sequences in the US-gag-pol
influence early and late pathogenic effects of Friend and Moloney murine leukemia viruses. J. Virol. 64:2135-2140.
48. Sitbon, M., L. Evans, J. Nishio, K. Wehrly, and B. Chesebro.
1986. Analysis of two strains of Friend murine leukemia viruses
differing in ability to induce early splenomegaly: lack of relationship with generation of recombinant mink cell focus-forming
viruses. J. Virol. 57:389-393.
49. Sitbon, M., J. Nishio, K. Wehrly, and B. Chesebro. 1985.
Pseudotyping of dual-tropic recombinant viruses generated by
infection of mice with different ecotropic murine leukemia
viruses. Virology 140:144-151.
50. Sitbon, M., J. Nishio, K. Wehrly, D. Lodmell, and B. Chesebro.
1985. Use of a focal immunofluorescence assay on live cells for
quantitation of retroviruses: distinction of host-range classes in
virus mixtures and biological cloning of dual-tropic murine
leukemia viruses. Virology 141:110-118.
51. Sitbon, M., B. Sola, L. Evans, J. Nishio, S. F. Hayes, K.
Nathanson, C. F. Garon, and B. Chesebro. 1986. Hemolytic
anemia and erythroleukemia, two distinct pathogenic effects of
Friend-MuLV: mapping of the effects to different regions of the
viral genome. Cell 47:851-859.
52. Speck, N. A., B. Renjifo, E. Golemis, T. N. Fredrickson, J. W.